A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches

Blockade of programmed cell death protein 1 (PD-1) immune checkpoint receptor signaling is an established standard treatment for many types of cancer and indications are expanding. Successful clinical trials using monoclonal antibodies targeting PD-1 signaling have boosted preclinical research, enco...

Descripción completa

Detalles Bibliográficos
Autores principales: Versteven, Maarten, Van den Bergh, Johan M.J., Broos, Katrijn, Fujiki, Fumihiro, Campillo-Davo, Diana, De Reu, Hans, Morimoto, Soyoko, Lecocq, Quentin, Keyaerts, Marleen, Berneman, Zwi, Sugiyama, Haruo, Van Tendeloo, Viggo F.I., Breckpot, Karine, Lion, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021243/
https://www.ncbi.nlm.nih.gov/pubmed/29963238
http://dx.doi.org/10.18632/oncotarget.25591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021243/
https://www.ncbi.nlm.nih.gov/pubmed/29963238
http://dx.doi.org/10.18632/oncotarget.25591

Ejemplares similares